Who knows really. It really becomes undeniable that the drug works if there's strong results in 3 indications in 3 different trails across 2 different countries.
The Q2 result wasn't what I expected, nor was it good, but it wasn't a disaster. Market will assume a further downgrade may occur but the commentary around the retention and patient adds is good. ACAD mentioned they had seen a positive change in net patient starts which was true, it just wasn't enough to maintain the guidance. 2 quarters of negative sales growth would be a disaster IMO.
Who knows really. It really becomes undeniable that the drug...
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.94 |
Change
-0.200(1.52%) |
Mkt cap ! $1.653B | |||
| Open | High | Low | Value | Volume |
| $13.03 | $13.06 | $12.75 | $7.500M | 581.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2300 | $12.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.96 | 2086 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |